Indaptus Therapeutics, Inc. to Post Q1 2024 Earnings of ($0.57) Per Share, HC Wainwright Forecasts (NASDAQ:INDP)

Indaptus Therapeutics, Inc. (NASDAQ:INDP) – Investment analysts at HC Wainwright cut their Q1 2024 EPS estimates for Indaptus Therapeutics in a report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.57) for the quarter, down from their prior estimate of ($0.44). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Indaptus Therapeutics’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS and FY2024 earnings at ($1.83) EPS.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07.

Indaptus Therapeutics Stock Down 5.3 %

Shares of INDP opened at $2.52 on Wednesday. The company has a market cap of $21.52 million, a price-to-earnings ratio of -1.37 and a beta of 1.28. Indaptus Therapeutics has a twelve month low of $1.56 and a twelve month high of $4.08. The company has a 50 day moving average of $2.15 and a two-hundred day moving average of $2.11.

Institutional Investors Weigh In On Indaptus Therapeutics

Institutional investors have recently bought and sold shares of the company. Citadel Advisors LLC acquired a new stake in shares of Indaptus Therapeutics during the fourth quarter worth $29,000. Northern Trust Corp purchased a new position in shares of Indaptus Therapeutics during the first quarter worth $41,000. Renaissance Technologies LLC purchased a new position in Indaptus Therapeutics in the second quarter valued at $51,000. State Street Corp purchased a new position in Indaptus Therapeutics in the first quarter valued at $78,000. Finally, Vanguard Group Inc. increased its holdings in Indaptus Therapeutics by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock valued at $451,000 after buying an additional 5,517 shares in the last quarter. 7.06% of the stock is currently owned by institutional investors and hedge funds.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.